Table 2. Association of EphA2 overexpression with clinicopathologic variables in endometrioid endometrial cancer.
N=139*** | ||||
---|---|---|---|---|
Low EphA2 | High EphA2 | p | ||
Stage | Low (I/II) | 61 | 47 | |
High (III/IV) | 10 | 19 | 0.04 | |
Grade | Low (1 or 2) | 65 | 47 | |
High (3) | 6 | 19 | 0.003 | |
Depth of invasion | ≤ 1/2 | 56 | 42 | |
> 1/2 | 15 | 24 | 0.047 | |
Node status | Negative | 40 | 34 | |
Positive | 25 | 24 | ||
Not done | 6 | 8 | 0.7 | |
ER* | Low | 28 | 41 | |
High | 43 | 25 | 0.01 | |
PR* | Low | 23 | 37 | |
High | 48 | 29 | 0.006 | |
Ki-67** | Low | 48 | 33 | |
High | 23 | 33 | 0.04 |
NOTE:
Low expression of ER and PR denotes negative, weak or moderate expression (SI = 0-8); high expression of ER and PR denotes strong expression (SI = 9-12).
Low expression of Ki-67 denotes ≤ 30% positive cells and high expression denotes > 30% positive cells.
Missing numbers denote samples that were damaged and could not be evaluated.